Swiss BASKET (Basel Stent Kosteneffektivitats Trial) trial finds evidence for restricting DES (drug-eluting stent) use
This article was originally published in Clinica
Executive Summary
Fuelling the debate over the widespread use of drug-eluting stents (DESs) for treating blocked arteries, a Swiss study of "real world" patients has challenged the notion that every patient should receive the device irrespective of their baseline characteristics.
You may also be interested in...
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.